Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT AND SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021)
5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES
6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES
6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING
6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS
6.2 RESTRAINTS
6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS
6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS
6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE
6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS
6.4 CHALLENGES
6.4.1 PRODUCT RECALLS
6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS
7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES
7.1 OVERVIEW
7.2 REAGENTS & CONSUMABLES
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES
7.4 SERVICES
8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE
8.1 OVERVIEW
8.2 VIRAL
8.2.1 CORONAVIRUS
8.2.2 INFLUENZA VIRUS
8.2.3 ADENOVIRUS
8.2.4 RHINOVIRUS
8.2.5 ROTAVIRUS
8.2.6 OTHERS
8.3 BACTERIAL
8.3.1 PNEUMONIAE
8.3.2 BORDETELLA PERTUSSIS
8.3.3 STAPHYLOCOCCUS
8.3.4 OTHERS
8.4 PARASITES
8.5 FUNGAL
9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE
9.1 OVERVIEW
9.2 RESPIRATORY INFECTIONS
9.3 GASTROENTERITIS
9.4 SEXUALLY TRANSMITTED INFECTIONS
9.5 SEPSIS
9.6 MENINGITIS
9.7 OTHERS
10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE
10.1 OVERVIEW
10.2 RESPIRATORY PANEL
10.3 GI-ENTERIC PANEL
10.4 SEXUALLY TRANSMITTED DISEASE PANEL
10.5 BLOOD-SEPSIS PANEL
10.6 MENINGITIS PANEL
10.7 OTHERS
11 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICAL LABORATORIES
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.5 RESEARCH INSTITUTES
11.6 OTHERS
12 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMÉRIEUX SA)
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 F. HOFFMANN-LA ROCHE LTD
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY
15.3.1 COMPANY SNAPSHOT
15.3.2 RECENT FINANCIALS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 CEPHEID (A SUBSIDIARY OF DANAHER)
15.4.1 COMPANY SNAPSHOT
15.4.2 RECENT FINANCIALS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 QIAGEN
15.5.1 COMPANY SNAPSHOT
15.5.2 RECENT FINANCIALS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AKONNI BIOSYSTEMS, INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 APPLIED BIOCODE, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 BD
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIOCARTIS
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 BIO-RAD LABORATORIES, INC.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH)
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.)
15.13.1 COMPANY SNAPSHOT
15.13.2 RECENT FINANCIALS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 HOLOGIC, INC.
15.14.1 COMPANY SNAPSHOT
15.14.2 RECENT FINANCIALS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 MIRXES PTE LTD.
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 NANŌMIX, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 PROMINEX INC.
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 QUANTUMDX GROUP LTD.
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.19 SEEGENE INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENTS
15.2 SIEMENS HEALTHCARE GMBH
15.20.1 COMPANY SNAPSHOT
15.20.2 RECENT FINANCIALS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENT
15.21 THERMOFISHER SCIENTIFIC INC.
15.21.1 COMPANY SNAPSHOT
15.21.2 RECENT FINANCIALS
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 COST OF THE PRODUCT
TABLE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA REAGENTS & CONSUMABLES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA INSTRUMENTS, SOFTWARE & ACCESSORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA SERVICES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA PARASITES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA FUNGAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA RESPIRATORY INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA GASTROENTERITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA SEXUALLY TRANSMITTED INFECTIONS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA SEPSIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA MENINGITIS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA RESPIRATORY PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA GI-ENTERIC PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA SEXUALLY TRANSMITTED DISEASE PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA BLOOD-SEPSIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA MENINGITIS PANEL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA HOSPITALS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA CLINICAL LABORATORIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA RESEARCH INSTITUTES IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA OTHERS IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 42 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 43 U.S. VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 44 U.S. BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 45 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 46 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 47 U.S. SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 48 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 49 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 50 CANADA VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 51 CANADA BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 52 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 53 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 54 CANADA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT AND SERVICES, 2020-2029 (USD MILLION)
TABLE 56 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 57 MEXICO VIRAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 58 MEXICO BACTERIAL IN SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE, 2020-2029 (USD MILLION)
TABLE 59 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 60 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE, 2020-2029 (USD MILLION)
TABLE 61 MEXICO SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF INFECTIOUS DISEASES IS EXPECTED TO DRIVE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN THE FORECAST PERIOD
FIGURE 12 REAGENTS & CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET
FIGURE 15 TOTAL CASES OF COVID-19 IN NORTH AMERICA
FIGURE 16 TOTAL CASES OF COVID-19 IN EUROPE
FIGURE 17 NATIONAL HEALTH EXPENDITURE VS MEDICAL DEVICE EXPENDITURE, U.S., 2019
FIGURE 18 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2021
FIGURE 19 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT & SERVICES, LIFELINE CURVE
FIGURE 22 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2021
FIGURE 23 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY INFECTION TYPE, LIFELINE CURVE
FIGURE 26 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2021
FIGURE 27 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY DISEASE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2021
FIGURE 31 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, 2022-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PANELS TYPE, LIFELINE CURVE
FIGURE 34 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2021
FIGURE 35 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: SNAPSHOT (2021)
FIGURE 39 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021)
FIGURE 40 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: BY PRODUCT AND SERVICES (2022-2029)
FIGURE 43 NORTH AMERICA SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)
